Treatment Group:Eculizumab Combined with Anti-CD20 Monoclonal Antibodies

2 trials

Sponsors

The First Affiliated Hospital, Zhejiang University School of Medicine

Conditions

ANCA-Associated Rapidly Progressive GlomerulonephritisAnti-Glomerular Basement Membrane (Anti-GBM) Antibody-Associated Glomerulonephritis

Phase 4

Prospective, Multicenter, Single-Arm Clinical Study on Eculizumab in the Treatment of Active ANCA-Associated Rapidly Progressive Glomerulonephritis

Active, not recruitingChiCTR2600122042

The First Affiliated Hospital, Zhejiang University School of MedicineANCA-Associated Rapidly Progressive Glomerulonephritis

Start: 2026-04-15Updated: 2026-04-14

Unknown Phase

Prospective, Multicenter, Single-Arm Clinical Study of Eculizumab Combined with CD20-Targeted Antibody in the Treatment of Anti-Glomerular Basement Membrane (Anti-GBM) Antibody-Associated Glomerulonephritis

Active, not recruitingChiCTR2600116985

The First Affiliated Hospital, Zhejiang University School of MedicineAnti-Glomerular Basement Membrane (Anti-GBM) Antibody-Associated Glomerulonephritis

Start: 2026-01-19Updated: 2026-01-27